FMC — FMC Corporation

FMC Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: $762 million, exceeding guidance by $12 million but down 4% year-over-year; up 1% on a like-for-like basis excluding India.
• Adjusted EBITDA: $72 million, $17 million above the high end of guidance.
• Adjusted Loss Per Share: $0.23, better than guidance by $0.15.
• Free Cash Flow: Negative $628 million, a decline from the prior year, with expectations for 2026 to range from negative $65 million to positive $65 million.
• Gross Debt: Approximately $4.5 billion, with net debt at $4.1 billion, reflecting a seasonal working capital build.

2. Strategic Updates and Business Highlights

• Operational Priorities: FMC is focused on debt reduction (targeting $1 billion in 2026), optimizing manufacturing costs, managing the post-patent transition for Rynaxypyr, and supporting sales growth of new active ingredients like Isoflex, fluindapyr, and Dodhylex.
• Debt Reduction Progress: Sale of the India commercial business is in advanced stages, with expectations to finalize by May. Additional asset sales and licensing agreements are also in negotiation.
• New Active Ingredients: Sales of new products doubled year-over-year in Q1, with Isoflex receiving EU regulatory approval, expected to launch in 2027.

3. Forward Guidance and Outlook

• Q2 Revenue Guidance: Expected between $850 million and $900 million, reflecting a 17% decline at the midpoint primarily due to lower sales to diamide partners and the removal of India.
• Full Year 2026 Guidance: Sales projected at $3.6 billion to $3.8 billion (5% decline at midpoint), EBITDA of $670 million to $730 million (17% decline), and adjusted EPS of $1.63 to $1.89 (41% decline).
• Second Half Expectations: Anticipated sales and EBITDA to be consistent with the prior year, driven by volume growth and new active ingredients.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Increased competition from low-cost generic products, particularly in Latin America and Asia, impacting margins and pricing strategies.
• Pricing Declines: Average prices down 6% in Q1, with significant contributions from Rynaxypyr partner sales, which are expected to decline further.
• Input Cost Uncertainty: Rising energy, transportation, and raw material costs due to geopolitical factors, particularly the conflict in Iran, could impact future pricing and margins.
• Interest Expense Increase: First quarter interest expense rose to $64.8 million, expected to increase further in 2026 due to higher borrowing costs.

5. Notable Q&A Insights

• Sales Organization Impact: Confidence in the second half is bolstered by a new sales organization in Brazil, which has already secured a significant number of orders.
• Rynaxypyr Strategy: The company is seeing early signs of share gains from other insecticide classes, particularly in North America, but acknowledges the need for continued focus on high-end product sales to combat generic competition.
• Tariff Recovery Potential: Discussions around potential refunds for tariffs are ongoing, with some categories appearing more likely to yield recoveries than others.
• New Product Pipeline: Isoflex is expected to become a major product in Europe, with strong initial demand and registration progress, while fluindapyr is also showing promising growth potential pending regulatory approvals.

Overall, FMC Corporation's Q1 2026 results reflect a mix of progress in strategic initiatives and challenges posed by market conditions and competitive pressures, with cautious optimism for the second half of the year.